IMAB362: a novel immunotherapeutic antibody targeting the tight-junction protein component CLAUDIN18.2 in gastric cancer

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter S. E. Al-Batran
Citation Annals of Oncology (2016) 27 (2): 1-3. 10.1093/annonc/mdw237
Authors S..E. Al-Batran, M. Schuler, Z. Zvirbule, G. Manikhas, F. Lordick, O. Tureci, C. Huber, U..S. Group
  • /

Abstract

Claudin18.2 (CLDN18.2) is a tight junction protein expressed by several cancers including gastric and GEJ adenocarcinoma. IMAB362 is a chimeric monoclonal antibody that mediates specific killing of CLDN18.2-positive cancer cells by activation of immune effector mechanisms.